Meta-analysis of 15 clinical trials concerning the treatment of advanced ovarian cancer with PD-L1 inhibitors showed limited efficacy due to relatively low microsatellite instability and tumor mutational burden overall in EOCs. Here, CD274 is linked to ovarian cancer.